Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7867554 | 0.90 | TAS1R3 (0.56) | NPSR1MAPTLMNATAS1R3TAS1R1 | |
| SCHEMBL7867528 | 0.90 | KMT2A (0.62) | NPSR1MAPTLMNATAS1R3TAS1R1 | |
| SCHEMBL7867583 | 0.89 | NPSR1 (0.58) | NPSR1MAPTLMNATAS1R3TAS1R1 | |
| SCHEMBL7876133 | 0.88 | NPSR1 (0.71) | NPSR1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL7867465 | 0.82 | NPSR1 (0.57) | NPSR1MAPTLMNATAS1R3TAS1R1 | |
| SCHEMBL7994479 | 0.81 | MAPT (0.46) | NPSR1MAPTLMNATAS1R3TAS1R1 | |
| SCHEMBL7867660 | 0.80 | NPSR1 (0.60) | NPSR1MAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL7874393 | 0.80 | NPSR1 (0.57) | NPSR1MAPTLMNATAS1R3TAS1R1 | |
| SCHEMBL7867322 | 0.80 | KMT2A (0.63) | NPSR1MAPTLMNATAS1R3TAS1R1 | |
| SCHEMBL7876188 | 0.79 | POLB (0.58) | NPSR1MAPTLMNASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0800505-B1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORP (US) | 2001-09-26 | — | — | EP | claimed |
| US-5801195-A | TUMOR NECROSIS AGENT INHIBITORS FOR COMBATING CACHEXIA, ENDOTOXIC SHOCK AND RETROVIRUS REPLICATION | CELGENE CORPORATION (US) | 1998-09-01 | — | — | US | claimed |
| US-5736570-A | ADMINISTERING TO REDUCE TUMOR NECROSIS FACTOR (TNFA) LEVELS IN MAMMAL; RETROVIRAL DISEASE TREATMENT/PROPHYLAXIS | CELGENE CORPORATION (US) | 1998-04-07 | — | — | US | claimed |
| EP-0800505-B1 | NOVEL IMMUNOTHERAPEUTIC ARYL AMIDES | CELGENE CORP (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6046221-A | USEFUL FOR REDUCING LEVELS OF TUMOR NECROSIS FACTOR-ALPHA IN A MAMMAL | CELGENE CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
| US-5801195-A | TUMOR NECROSIS AGENT INHIBITORS FOR COMBATING CACHEXIA, ENDOTOXIC SHOCK AND RETROVIRUS REPLICATION | CELGENE CORPORATION (US) | 1998-09-01 | — | — | US | disclosed |
| US-5736570-A | ADMINISTERING TO REDUCE TUMOR NECROSIS FACTOR (TNFA) LEVELS IN MAMMAL; RETROVIRAL DISEASE TREATMENT/PROPHYLAXIS | CELGENE CORPORATION (US) | 1998-04-07 | — | — | US | disclosed |